A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor-Hair Serum for the Prevention of Chemotherapy-Induced Alopecia

This nonrandomized clinical trial evaluated the effectiveness of Keratinocyte Growth Factor-Hair Serum (KGF-HS) in preventing chemotherapy-induced alopecia (CIA) in 28 patients with early-stage breast cancer, with 20 completing the trial. The study found that KGF-HS application led to hair preservation in some patients, defined as less than 50% hair loss, although two patients withdrew due to Grade 1 pruritus. Despite these findings, the trial's small sample size and open-label design limit its conclusions, and further research, including a randomized double-blind placebo-controlled study, is necessary to confirm the potential of KGF-HS in reducing CIA.